The FDA has accepted the BLA for crovalimab, an investigational treatment for paroxysmal nocturnal hemoglobinuria. Tranexamic acid did not seem to increase risk of postoperative complications in patients undergoing total joint arthroplasty. The CHMP of the European Medicines Agency supported approving avapritinib for indolent systemic mastocytosis in Europe. Markers of pulmonary impairment and inflammation were elevated in children with sickle cell disease and acute chest syndrome. Dr. Masarova spoke with HemeToday on findings from a treatment comparison of pacritinib and momelotinib in myelofibrosis. Testosterone replacement therapy improved anemia remission and new anemia prevention versus placebo in men with hypogonadism. Asymptomatic DVT incidence was similar in patients with benign and malignant diseases prior to surgery for benign disease. Patients treated for isolated superficial vein thrombosis with anticoagulants still had a "substantial" risk of VTE later on. Splenomegaly and myeloproliferative disorders increased risk for porto-spleno-mesenteric venous thrombosis after splenectomy. Fostamatinib improved hemoglobin response in warm antibody autoimmune hemolytic anemia versus placebo in the FORWARD trial. A FDA Advisory Committee endorsed the safety of exa-cel, a genetic therapy with the potential to cure sickle cell disease. Efgartigimod, a first-in-class IgG1 Fc fragment, promisingly separated from placebo in patients with chronic ITP. Plasma thrombopoietin was significantly higher in aplastic anemia and myelodysplastic syndromes compared with control values. MPN-associated vascular thromboembolisms were more common in JAK2-mutated diseases and less common in CALR-mutated diseases. Edoxaban therapy for 12 months was superior to three-month therapy for preventing venous thromboembolisms and related deaths. HSCT from a haploidentical donor and PTCy improved neutrophil and platelet engraftment compared with UCBT in aplastic anemia. Von Willebrand factor concentrate was not superior to tranexamic acid for reducing heavy menstrual bleeding in women. Iptacopan, a complement factor B inhibitor, was effective in patients with PNH with active hemolysis despite eculizumab use. Subclinical leaflet thrombosis appears more common after TAVR versus SAVR, but was not associated with increased stroke risk. Meta-analysis findings support the use of statins in patients with PV and ET to reduce mortality and thrombosis risk.